Murphy & Mullick Capital Management’s AbbVie ABBV Stock Holding History

Murphy & Mullick Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$131K	Sell	522 -1	-0.2%	-$215	0.08%	184
2026 Q1	$114K	Buy	523 +1	+0.2%	+$222	0.08%	183
2025 Q4	$119K	Buy	522 +2	+0.4%	+$456	0.09%	187
2025 Q3	$120K	Buy	520 +1	+0.2%	+$204	0.09%	181
2025 Q2	$97.8K	Hold	519	–	–	0.08%	191
2025 Q1	$109K	Sell	519 -19	-4%	-$3.69K	0.11%	170
2024 Q4	$95.6K	Buy	+538	New	+$98.9K	0.09%	176

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Murphy & Mullick Capital Management's ABBV Position: Q2 2026 in Review

Murphy & Mullick Capital Management reduced its AbbVie (ABBV) stake by 0.19% in Q2 2026, selling an estimated $215 and leaving 522 shares worth $131K. The position accounts for 0.08% of the portfolio, ranked #184.

Murphy & Mullick Capital Management first reported a position in ABBV in Q4 2024 and has held it in 7 quarters since. 4,215 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Murphy & Mullick Capital Management held 522 shares of AbbVie worth $131K as of Q2 2026.
Murphy & Mullick Capital Management sold 1 AbbVie share in Q2 2026, an estimated $215.
AbbVie made up 0.08% of Murphy & Mullick Capital Management's portfolio in Q2 2026, its #184 holding.
Murphy & Mullick Capital Management first reported a position in AbbVie in Q4 2024 and has held it in 7 quarters since.
4,215 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Murphy & Mullick Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.